Intracytoplasmic sperm injection

Mol Cell Endocrinol. 2002 Jan 25;186(2):199-203. doi: 10.1016/s0303-7207(01)00658-x.

Abstract

Intracytoplasmic sperm injection (ICSI) with ejaculated, epididymal or testicular spermatozoa was first successful in 1992 and has since become the widely accepted treatment for couples with severe male-factor infertility. The outcome of several thousands of ICSI cycles in terms of fertilization, embryo cleavage and implantation is similar to that for conventional in-vitro fertilization in couples with tubal or idiopathic infertility. To evaluate the important issue of safety of the new technique of ICSI, a prospective follow-up study of children born after ICSI was carried out. The aim was to compile data on karyotypes, congenital malformations, growth parameters and developmental milestones. Parents' agreement to genetic counseling was obtained, as well as prenatal diagnosis, followed by a physical examination of the children at 2 months, 1 and 2 years. Important outcome data to be examined comprise information on major and minor congenital malformations obtained prenatally or after birth, as well as on the further development of the children.

Publication types

  • Review

MeSH terms

  • Adult
  • Chromosome Disorders / epidemiology
  • Chromosome Disorders / etiology
  • Chromosome Disorders / genetics
  • Congenital Abnormalities / epidemiology
  • Congenital Abnormalities / etiology
  • Congenital Abnormalities / genetics
  • Female
  • Fertilization in Vitro / methods*
  • Follow-Up Studies
  • Humans
  • Infant, Newborn
  • Intellectual Disability / epidemiology
  • Intellectual Disability / etiology
  • Intellectual Disability / genetics
  • Karyotyping
  • Male
  • Microinjections*
  • Oocytes
  • Pregnancy
  • Pregnancy Outcome
  • Pregnancy, Multiple
  • Safety
  • Spermatozoa*